The Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1272, New York, NY-10029, USA.
The Department of Urology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1272, New York, NY-10029, USA.
Urol Clin North Am. 2020 Nov;47(4S):e17-e54. doi: 10.1016/j.ucl.2020.10.005.
Bladder cancer has been successfully treated with immunotherapy, whereas prostate cancer is a cold tumor with inadequate immune-related treatment response. A greater understanding of the tumor microenvironment and methods for harnessing the immune system to address tumor growth will be needed to improve immunotherapies for both prostate and bladder cancer. Here, we provide an overview of prostate and bladder cancer, including fundamental aspects of the disease and treatment, the elaborate cellular makeup of the tumor microenvironment, and methods for exploiting relevant pathways to develop more effective treatments.
膀胱癌已成功采用免疫疗法治疗，而前列腺癌则是一种免疫相关治疗反应不足的“冷肿瘤”。为了改善前列腺癌和膀胱癌的免疫疗法，我们需要更深入地了解肿瘤微环境以及利用免疫系统来解决肿瘤生长的方法。在此，我们对前列腺癌和膀胱癌进行概述，包括疾病和治疗的基本方面、肿瘤微环境的精细细胞组成，以及利用相关途径开发更有效的治疗方法。
